Technology Platform

MonoTx® operates a public umbilical cord blood bank that serves as the foundation of its platform. All cord blood units are collected from healthy, consenting donors following full-term deliveries. These donors undergo comprehensive screening for maternal infectious diseases, which include testing for hepatitis B, hepatitis C, HIV-1/2, syphilis, cytomegalovirus, Western Nile virus, and the human T-lymphotropic virus.

The MonoTx® cord blood bank is:

  • AABB-accredited
  • Registered with the U.S. FDA as a Human Cell & Tissue Establishment
  • Affiliated with the World Marrow Donor Association (WMDA)

The bank stores more than 10,000 high-quality cord blood cell packs for both clinical and translational research.

MonoTx® employs the automated, closed, GMP-compatible processing system to fractionate fresh umbilical cord blood into two primary components:

Fraction

Composition

Therapeutic Application

Mononuclear Cells (MNCs)

Lymphocytes, monocytes, hematopoietic and endothelial progenitor cells

Neurological repair (spinal cord injury (SCI), hypoxic-ischemic encephalopathy (HIE), stroke) via paracrine-induced neurogenesis

Cell-Free Plasma

Exosomes, growth factors, cytokines, platelets

Source material for ERP® exosomes across various indications

This automated separation step, covered by the licensed patent portfolio, establishes a clean plasma source optimized for downstream exosome isolation while preserving cellular fractions for therapeutic applications.

Proprietary Exosome Isolation Technology

Exosomes are exclusively isolated from the plasma fraction of umbilical cord blood using MonoTx’s patented polyethylene glycol (PEG)–based precipitation technology. The process involves plasma clarification, PEG-mediated exosome precipitation under controlled cold incubation, low-speed centrifugation to collect exosomes. This method delivers high recovery efficiency and preserves exosome integrity.